Click the button to 'Like' this message on Facebook

Casino Night:

On October 12th, the Schilling Family held the 1st annual "Casino Night" fundraising event in Jacksonville for the Foundation. There were approximately 55 people in attendance. The event was very successful raising nearly $10,000.00.


Halloween Fundraising Event

On October 30th, the office staff of Dr. Gina Schell conducted a Halloween Fundraising event ar Ricky P's Restaurant downtown St. Peetersburg. There were nearly 25 opportunity drawings and a costume contest for adults and children. Nearly 100 people attended which resulted in nearly $1,200 being raised for the Foundation.


If you would like to host a fundraising event, contact Rick McCollum at (727) 447-7075 or email Rick at

Nonadherence to hydroxychloroquine seen in 15% of SLE patients

 Fifteen percent of patients with systemic lupus erythematosus had complete nonadherence to hydroxychloroquine therapy, while a larger percentage of patients had only partial adherence, according to research presented at the American College of Rheumatology annual meeting.
•  

How Mental and Emotional Health Affect Lupus

Anyone who has lupus understands that this disease impacts more than a person’s physical wellness. It can also negatively impact a person’s mental and emotional wellness. It can be very easy for a person with this condition to give into the fatigue and depression that this disease brings with it. However, doctors agree that people who want to adjust, if not overcome, this lupus diagnoses should remember that their mental and emotional state can play a major role in keeping their condition in remission.
•  

Lupus drug sales "to reach $4 billion by 2022"

Sales of drugs to treat systemic lupus erythematosus (SLE) are set to soar from just $900 million in 2012 to $4 billion by 2022, according to new forecasts.


GlaxoSmithKline’s Benlysta (belimumab), the first biologic drug approved for the disease, will be the primary driver of market growth in the US, France, Germany, Italy Spain, the UK and Japan, where its sales will reach $1.1 billion in 2022, says the study, from Decision Resources.

•  
Rituximab Defeats IgG4-Related Disease in Open-Label Study

Rituximab has proven uniformly and resoundingly effective against the baffling syndrome known as IgG4-related disease (IgG4-RD), in a small prospective uncontrolled study funded by Genentech and carried out at Massachusetts General Hospital and the Mayo Clinic. The drug quickly resolved symptoms, reduced IgG4 levels dramatically, and allowed patients to discontinue steroids (the only medications currently effective against the syndrome's wide range of fibro-inflammatory symptoms), reported John Stone MD at the 2013 annual meeting of the American College of Rheumatology in San Diego.


IgG4-RD was first described only 10 years ago, and is often mistaken for a range of other rheumatic conditions including Sjogrens syndrome, lupus, and sarcoidosis. It is the primary cause of retroperitoneal fibrosis, but also causes lymphadenopathy and painful, disfiguring fibrosis of the salivary and lacrimal glands and the orbits.


•  
Autism and ADHD Risk Increased for SLE Offspring

As well as neonatal lupus and heart block, new research from Canada suggests that children born to women with systemic lupus erythematosus (SLE) may face a higher risk for autism and attention deficit hyperactivity disorder (ADHD).

The risk for autism spectrum disorders (ASDs) appears to be twice as high for children of women who have SLE than for those of healthy women, possibly because of exposure to autoimmune antibodies, according to Evelyne Vinet MD, assistant professor in the department of rheumatology at McGill University Health Center in Montreal. The risk for AHDH seems to be related to medication exposure,

•  
Solving Catch 22 in Failed SLE Drug Trials: Don't Treat Control Group?

Lupus experts have suspected that proposed new treatments for systemic lupus erythematosus (SLE) are set up to fail: In clinical trials, even the modest success of standard lupus treatments used in the comparison group set the bar for statistically significant improvement impossibly high.

Of course, it's unethical not to give standard treatment to the control group. Or is it? Researchers have been testing the feasibility of simply stopping treatment for the control group in clinical trials of SLE, and they find it has promise.

•  
Pregnancy Complications Avoidable in SLE and APS

In-vitro fertilization can succeed for women with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS), but may increase the risk of flares or blood clots if they do not adhere to treatment.regimens, according to one of several studies on pregnancy problems among women with these conditions reported at the 2013 annual meeting of the American College of Rheumatology.

The retrospective study of 34 women with SLE and/or APS who underwent at least one cycle of IVF in France shows 92% had successful pregnancies. However, 10% had hormone-related flares or thromboses, often due to poor treatment adherence, researchers said.

•  
Both Risks and Costs are Double in Lupus Pregnancies

A retrospective analysis of more than 10,700 pregnancies among women with and without systemic lupus erythematosus (SLE) shows doubled risks for hypertension, preeclampsia, preterm delivery, and stillbirths among women who have SLE.

The analysis of a US administrative healthcare claims database also finds a more than 16-fold occurrence of nephritis in SLE pregnancies.

The review, presented at the 2013 annual meeting of the American College of Rheumatology in San Diego, analyzed data from 1,721 SLE pregnancies and 8,605 non-SLE pregnancies from 2006 to 2012.

•  
Spread the Word

Send an HTML version of this message to a friend.